Form 4: Emergent BioSolutions Exec's Stock Transactions

Emergent BioSolutions SVP Simon Lowry reported the acquisition of new stock options and the sale of shares for tax purposes.

Summary

• Simon C. Lowry, SVP, R&D, CMO of Emergent BioSolutions Inc. (EBS), reported transactions involving company securities.
• On March 5, 2026, Lowry disposed of 10,636 shares of common stock at a price of $8.44 per share. This transaction was for the purpose of satisfying tax withholding obligations related to the vesting and settlement of restricted stock units.
• Following this disposal, Lowry directly beneficially owns 77,803 shares of common stock.
• On March 3, 2026, Lowry acquired 44,834 employee stock options with an exercise price of $8.99 per share.
• These options will vest in three equal installments, beginning on the day prior to the anniversary date of the grant, and have an expiration date of March 2, 2033.
• After this acquisition, Lowry directly beneficially owns 147,833 derivative securities (employee stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing. While there was a disposal of shares, it was for tax purposes, which is a routine event. The significant grant of new stock options to a key executive aligns management's interests with long-term shareholder value, contributing to a slightly positive sentiment.

Positives

• Grant of 44,834 new employee stock options aligns executive incentives with long-term shareholder value.
• The options have an exercise price of $8.99, providing potential future upside for the executive.

Negatives

• Disposal of 10,636 shares of common stock, reducing direct beneficial ownership of non-derivative securities, although this was for tax withholding.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider trading activity, providing transparency into executive compensation and ownership changes rather than broader industry trends. These transactions reflect standard executive compensation practices within the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders gain transparency into executive compensation and ownership changes, which can inform their assessment of management's alignment with shareholder interests.
• The grant of stock options incentivizes the SVP, R&D, CMO, to contribute to the company's long-term performance.

Next Steps

• Employee stock options will vest in three equal installments beginning on the day prior to the anniversary date of the grant.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation and tax obligations. While it shows an executive receiving new stock options, it does not provide sufficient information to alter a fundamental investment thesis for Emergent BioSolutions Inc. The sale of shares was for tax withholding, not a discretionary sale, and the new option grant aligns executive incentives with shareholder value over the long term. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Emergent BioSolutions, EBS, Insider Trading, Form 4, Stock Options, Restricted Stock Units, Executive Compensation, Biotechnology, Pharmaceuticals